12 results about "Egfr tki" patented technology

The application discloses an evaluation method for predicting the safety of EGFR TKIs monotherapy for NSCLC. The method comprises the following steps: obtaining the data of a plurality of patients receiving EGFR TKIs treatment; taking MDRAE (maximum grade of drug-related adverse event) as a safety index, constructing a safety evaluation final model, and the final model is an ordered logistic regression model, the covariates of the final model include normalized steady-state trough concentration, EGFR TKIs treatment history, gender, baseline glutamyltransferase, baseline uric acid, baseline creatine kinase, baseline platelets and baseline lymphocytes; obtaining the data of a target patient, inputting the numerical values of each covariate in the data of the target patient into the final model; determining the first probability of MDRAE of the target patient being grade 3 and above, the second probability of MDRAE being grade 2 and the third probability of MDRAE being grade 1 and below according to the final model, and taking the grade corresponding to the maximum probability in the three probabilities as the predicted grade of MDRAE of the target patient. The application improves the accuracy of predicting the safety of EGFR TKIs monotherapy for NSCLC.

The invention belongs to the technical field of biological medicine, and particularly relates to application of an integrated single base editor combined with EGFR-TKI in treatment of cis EGFRT790M / C797S mutation NSCLC. The invention provides an application for preventing drug resistance and a drug combination means for treating drug resistance, so that the treatment validity period of the existing first-generation EGFR TKI can be prolonged, the occurrence time of drug resistance can be delayed, and the lifetime of a patient can be prolonged.

The invention discloses application of berberine in preparation of a medicine for treating non-small cell lung cancer, and belongs to the technical field of biological medicine. The invention provides an application of berberine in preparation of a medicine for inhibiting or treating EGFR (epidermal growth factor receptor) driven diseases, or an application of berberine combined with other medicines in preparation of a medicine for inhibiting or treating EGFR driven diseases. The diseases comprise non-small cell lung cancer driven by EGFR (epidermal growth factor receptor). It is found that in PC-9 cells, berberine induces ROS accumulation and starts a mitochondrial injury pathway, then mitochondrial membrane potential is reduced, GSDME is activated to form an active N-terminal fragment (GSDME-N), then pyroptosis is induced, NSCLC cell proliferation is inhibited, and berberine is expected to overcome or delay EGFR TKI drug resistance and improve clinical effects and survival prognosis.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with an inhibitor of c-MET.

The invention discloses a combined medication method for enhancing the anti-tumor curative effect of an EGFR tyrosine kinase inhibitor. The invention finds that the combination of EGFR TKI and interferon prodrug has a synergistic effect on cancer treatment for the first time, and has no obvious toxic or side effect. The invention provides a brand new scheme for the research field of cancer treatment by EGFR TKI, provides a new treatment choice for EGFR TKI drug-resistant patients, has important scientific significance and clinical application value, and has wide application prospects.

The invention provides a TTF early warning method and system aiming at EGFR TKIs single drug intervention NSCLC, and is applied to the technical field of medical data processing. The method comprises the following steps: processing patient data to generate treatment failure time data; constructing a time-dependent Cox model, describing the influence of each variable on a risk function through the model, calculating the risk ratio among the variables based on the risk function model, and generating risk ratio data; analyzing each covariable based on a univariate time-dependent Cox model, screening variables with statistical significance or clinical correlation with patient survival in the univariate time-dependent Cox model, and adding the screened variables into a multivariate time-dependent Cox model; processing the multivariable time dependence Cox model based on parameter accuracy, proportional risk hypothesis test, akaike information criterion, consistency index and clinical correlation to generate a model evaluation result; and processing the target patient information to generate target scoring information.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an HS2ST1 inhibitor in preparation of a medicine for treating EGFR-TKI drug-resistant tumors. According to the invention, HS2ST1 is identified as a new action target of EGFR TKI drug resistance for the first time, and the expression of HS2ST1 in EGFR TKI drug-resistant cells is found to be remarkably up-regulated. Further functional experiments show that targeted inhibition of HS2ST1 can effectively enhance the drug sensitivity of EGFR TKI and reverse the drug resistance phenotype. In addition, mechanism exploration proves that the drug resistance promoting function of the HS2ST1 depends on the enzymatic activity of the HS2ST1; the enzyme activity is inactivated through a molecular means, and the drug resistance effect mediated by the HS2ST1 can be successfully reversed. The invention not only discloses a novel biological effect of HS2ST1 in EGFR-TKI drug resistance, but also provides a key theoretical basis and experimental support for subsequent development of an HS2ST1 small-molecule inhibitor and further overcoming of clinical drug resistance in combination with EGFR-TKI drugs such as osimertinib and the like.

The present invention relates to the treatment of cancer and particularly of lung cancer. In the present study, the inventors analyzed the role of the Notch pathway in EGFR-driven lung adenocarcinoma (LUAD) using complex genetic mouse models and patient derived xenografts. They found that, similarly to KRAS-driven LUAD, EGFR-driven LUAD shows both Notch pathway hyperactivation and addiction to its activity. Importantly, combination of EGFR tyrosine Kinase Inhibitors (TKIs) with Notch inhibition re-sensitizes LUAD cells harboring gatekeeper mutations EGFRT790M or EGFRC797S to gefitinib and osimertinib, respectively. Moreover, they show that pSTAT3, which is known to increase upon EGFR TKI treatment, directly binds to the HES1 promoter and represses HES1 expression. Finally, high HES1 expression levels correlate with shorter progression free survival and its expression increases upon progression in EGFR mutated patients under TKI treatment. Thus, the present invention relates to a combination of a tyrosine-kinase inhibitor (TKI) against epidermal growth factor receptor (EGFR) and an inhibitor of the Notch signalling pathway for use in the treatment of a cancer in a subject in need thereof.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.

The descriptive memorandum refers to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of previously EGFR TKI-naïve patients with metastatic or locally advanced EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with platinum-based chemotherapy and pemetrexed.

The present application relates to the technical field of biological medicine, and provides a lung cancer combined treatment composition, which comprises a C1GALT1 inhibiting drug and a Tn antigen related immunotherapy agent.The advantages are as follows: (1) the present application significantly improves the treatment effect on lung cancer through the synergistic effect of the C1GALT1 inhibition and the Tn related immunotherapy agent, provides a new treatment scheme for improving the clinical prognosis of lung cancer with EGFR mutation, and provides a new research direction for lung cancer treatment; (2) it is revealed that the EGFR TKI targeted drug inhibits the expression of C1GALT1 through the PI3K / AKT / SP1 pathway, blocks the subsequent glycosylation process of the Tn antigen, and up-regulates the expression of the Tn antigen in tumor cells, which indicates that the combination of the Tn antigen and the immunotherapy agent can improve the anti-lung cancer effect.

The present invention relates to a composition for treating third-generation EGFR TKI-resistant lung cancer, the composition comprising a Caesalpinia sappan L extract and Osimertinib. Co-administration of a Caesalpinia sappan L extract and Osimertinib according to the present invention has a synergistic effect on cytotoxicity in third-generation EGFR TKI-resistant lung cancer cell lines and was found to inhibit the proliferation of tumor cells by inhibiting mitochondrial membrane potential. In addition, the co-administration regulates the expression of apoptosis-related proteins and was found to reduce tumor volume in a third-generation EGFR TKI-resistant lung cancer animal model.